Rights issue 2018

Disclaimer

Rights issue in Sprint Bioscience AB (publ)

IMPORTANT INFORMATION

You have selected a website that is not intended for release, publication or distribution, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the United States of America or any other country where the offer or distribution of the prospectus would require additional registration or other measures than those required by Swedish law. It is the responsibility of each person to comply with such restrictions under laws and regulations outside Sweden. By accessing the documents on this part of the company's website, you also accept the terms and conditions for access to this website. Applications for subscription of units in violation of the above restrictions may be invalid.

Sprint Bioscience has not taken and will not take any action to authorise a public offering in any jurisdiction other than Sweden. The unit rights, paid subscription units or new shares or warrants covered by the offering have not been and will not be registered under the United States Securities Act of 1933, as amended. The prospectus and the rights issue are governed by Swedish law. Disputes arising from the prospectus, the rights issue and related legal matters shall be settled exclusively by Swedish courts, whereby the Stockholm District Court shall be the court of first instance.

By accessing the documents on this part of the Company's website, you confirm and undertake that (i) you have read and accept the conditions and restrictions set out above and (ii) you are not located in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the United States or in any other country where the offer or distribution of the prospectus would require additional registration or other measures than those required by Swedish law.